July 8 (Reuters) - Biogen Inc said on Wednesday that it submitted the marketing application for its experimental Alzheimer’s disease therapy, aducanumab, to the U.S. Food and Drug Administration. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)

Source: Reuters

Powered by NewsAPI.org